INFEX Therapeutics
Infex Therapeutics operates the AMR Centre, a research and development organisation focused on discovery and development of new antibacterial therapeutics. Activities described on the site include nomination of preclinical candidates (including programs targeting metallo-β-lactamases), co-development agreements for antimicrobial peptides and other antibacterial programs, early-phase clinical trial activity, laboratory infrastructure expansion, and engagement with public-private consortia, industry alliances and policy initiatives addressing antimicrobial resistance (AMR).
Industries
N/A
Products
Early-stage antibiotic clinical development program (Phase I/II)
An early-stage clinical program for an antibacterial candidate with documented dosing approvals for Phase Ia cohorts and initiation of Phase IIa first-in-patient studies.
Early-stage antibiotic clinical development program (Phase I/II)
An early-stage clinical program for an antibacterial candidate with documented dosing approvals for Phase Ia cohorts and initiation of Phase IIa first-in-patient studies.
Services
Co-development and collaborative R&D
Partnership agreements to jointly develop antibacterial therapeutics, including shared research and development activities with industry partners.
Early-phase clinical development support
Management and execution support for early-phase clinical studies (Phase I/II) for antibacterial programs.
Co-development and collaborative R&D
Partnership agreements to jointly develop antibacterial therapeutics, including shared research and development activities with industry partners.
Early-phase clinical development support
Management and execution support for early-phase clinical studies (Phase I/II) for antibacterial programs.
Expertise Areas
- Antibiotic discovery and development
- Preclinical candidate development
- Antimicrobial peptide therapeutics
- Clinical trial management (Phase I/II)
Key Technologies
- Metallo-β-lactamase inhibition
- Antimicrobial peptides
- Antibacterial drug discovery
- Preclinical efficacy models (in vitro and in vivo)